Form 8-K - Current report:
SEC Accession No. 0001437749-25-036006
Filing Date
2025-11-21
Accepted
2025-11-21 16:33:36
Documents
14
Period of Report
2025-11-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20251121_8k.htm   iXBRL 8-K 21714
6 logobig.jpg GRAPHIC 19220
  Complete submission text file 0001437749-25-036006.txt   207579

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20251120.xsd EX-101.SCH 3580
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20251120_def.xml EX-101.DEF 11808
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20251120_lab.xml EX-101.LAB 15859
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20251120_pre.xml EX-101.PRE 12023
16 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20251121_8k_htm.xml XML 2945
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251508485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)